PapersPMID:34836346
A Comparative Study of the Hepatoprotective Effect of Centella asiatica Extract (CA-HE50) on Lipopolysaccharide/d-galactosamine-Induced Acute Liver Injury in C57BL/6 Mice.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- animal · not in humans · 14 days
What moved
How to read these marks →- Decreases aspartate aminotransferase
insufficient
“The AST levels decreased significantly in the CA-HE50, silymarin, LEM, UDCA and DDB administration groups compared to the vehicle control group (p < 0.01; Figure 3A).”
- Interests
- Industry funded
- Dose studied
- 100 and 200 mg/kg CA-HE50 by oral gavage every 24 h for 2 weeks
- Population
- Male C57BL/6 mice with acute liver injury induced by intraperitoneal LPS and D-galactosamine after 2 weeks of pretreatment, compared with vehicle-treated injured mice
- Decreases alanine aminotransferase
insufficient
“In particular, ALT levels significantly decreased in the group administered 200 mg/kg of CA-HE50 (p < 0.01) and 200 mg/kg of DDB (p < 0.01; Figure 3B).”
- Interests
- Industry funded
- Dose studied
- 200 mg/kg CA-HE50 by oral gavage every 24 h for 2 weeks
- Population
- Male C57BL/6 mice with acute liver injury induced by intraperitoneal LPS and D-galactosamine after 2 weeks of pretreatment, 200 mg/kg dose stratum only, compared with vehicle-treated injured mice
Study record
- Design
- animal study, in vivo
- Species
- animal
- Population
- Six-week-old C57BL/6 mice with lipopolysaccharide/D-galactosamine-induced acute liver injury, given oral Centella asiatica 50% ethanol extract (CA-HE50) or positive-control hepatoprotectants
- Participants
- 48
- Comparator
- an active treatment / placebo
- Duration
- 14 days
- Endpoints measured
- 35